Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH)

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 998-1009

  Salaga M ^a   Mokrowiecka, A ^a   Zakrzewski, P K ^b   Cygankiewicz, A ^b   Leishman, E ^c   Sobczak, M ^a   Zatorski, H ^a   Malecka Panas E ^a   Kordek, R ^d   Storr, M ^a   Krajewska, W M ^b   Bradshaw, H B ^c   Fichna, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Experimental colitis; Fatty acid amide hydrolase; ; Inflammatory bowel diseases; ; Intestinal inflammation; ; PF 3845;

Indexed keywords

ARACHIDONIC ACID; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; GLYCINE; OLEIC ACID; PF 3845; PROSTAGLANDIN; UNCLASSIFIED DRUG; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; AMIDASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; FATTY-ACID AMIDE HYDROLASE; INDOLE DERIVATIVE; IODOPRAVADOLINE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; FATTY ACID AMIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; EXPERIMENTAL COLITIS; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COLITIS, ULCERATIVE; DISEASE MODEL; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; TREATMENT OUTCOME; ANIMAL TISSUE; GENE EXPRESSION; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

AMIDOHYDROLASES; ANIMALS; CANNABINOIDS; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PYRAZOLES; PYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TREATMENT OUTCOME;

EID: 84906790983     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.025     Document Type: Article

References (37)

1. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
2. Jump R.L., Levine A.D. Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:462-478.
3. Strobach R.S., Ross A.H., Markin R.S., Zetterman R.K., Linder J. Neural patterns in inflammatory bowel disease: an immunohistochemical survey. Mod Pathol 1990, 3:488-493.
4. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
5. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
6. Izzo A.A., Sharkey K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010, 126:21-38.
7. Hiley C.R., Ford W.R. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 2004, 79:187-205.
8. Svizenska I., Dubovy P., Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-a short review. Pharmacol Biochem Behav 2008, 90:501-511.
9. Ralevic V. Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol 2003, 472:1-21.
10. Lepicier P., Bibeau-Poirier A., Lagneux C., Servant M.J., Lamontagne D. Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci 2006, 102:155-166.
11. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001, 98:9371-9376.
12. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993, 46:791-796.
13. Bradshaw H.B., Lee S.H., McHugh D. Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins Other Lipid Mediat 2009, 89:131-134.
14. Bradshaw H.B., Rimmerman N., Hu S.S., Burstein S., Walker J.M. Novel endogenous N-acyl glycines identification and characterization. Vitam Horm 2009, 81:191-205.
15. D'Argenio G., Valenti M., Scaglione G., Cosenza V., Sorrentini I., Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006, 20:568-570.
16. Storr M.A., Keenan C.M., Emmerdinger D., Zhang H., Yuce B., Sibaev A., et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) 2008, 86:925-936.
17. Massa F., Marsicano G., Hermann H., Cannich A., Monory K., Cravatt B.F., et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004, 113:1202-1209.
18. Fichna J., Dicay M., Lewellyn K., Janecka A., Zjawiony J.K., MacNaughton W.K., et al. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 2012, 18:1137-1145.
19. Fichna J., Sibaev A., Salaga M., Sobczak M., Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil 2013, 25:e550-e559.
20. Fichna J., Mokrowiecka A., Cygankiewicz A.I., Zakrzewski P.K., Malecka-Panas E., Janecka A., et al. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?. Neurogastroenterol Motil 2012, 24:e557-e560.
21. Alhouayek M., Muccioli G.G. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 2012, 18:615-625.
22. Di S.A., Battista N., Biancheri P., Rapino C., Rovedatti L., Astarita G., et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 2011, 4:574-583.
23. Kimball E.S., Schneider C.R., Wallace N.H., Hornby P.J. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006, 291:G364-G371.
24. Lapoint J., James L.P., Moran C.L., Nelson L.S., Hoffman R.S., Moran J.H. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011, 49:760-764.
25. Rawls S.M., Benamar K. Effects of opioids, cannabinoids, and vanilloids on body temperature. Front Biosci (Schol Ed) 2011, 3:822-845.
26. Ovadia H., Wohlman A., Mechoulam R., Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995, 34:175-180.
27. Smirnov M.S., Kiyatkin E.A. Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats. Brain Res 2008, 1228:145-160.
28. Borrelli F., Aviello G., Romano B., Orlando P., Capasso R., Maiello F., et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) 2009, 87:1111-1121.
29. Jamontt J.M., Molleman A., Pertwee R.G., Parsons M.E. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 2010, 160:712-723.
30. Schicho R., Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012, 89:149-155.
31. Capasso R., Borrelli F., Aviello G., Romano B., Scalisi C., Capasso F., et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 2008, 154:1001-1008.
32. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108:1687-1707.
33. Farquhar-Smith W.P., Rice A.S. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 2003, 99:1391-1401.
34. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003, 125:677-687.
35. Dey I., Chadee K. Prostaglandin E2 produced by Entamoeba histolytica binds to EP4 receptors and stimulates interleukin-8 production in human colonic cells. Infect Immun 2008, 76:5158-5163.
36. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
37. Marquez L., Suarez J., Iglesias M., Bermudez-Silva F.J., Rodriguez de Fonseca F., Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 2009, 4:e6893.